Eli Lilly Shares Tumble 10% After Q1 Earnings Miss Wall Street Estimates
Eli Lilly (NYSE:LLY) shares slumped more than 10% on Thursday after the pharmaceutical giant posted weaker-than-expected earnings for the first quarter, missing Wall Street estimates by $0.12 per share.
The Indianapolis-based company reported earnings per share of $3.34, compared with analysts' forecast of $3.46. Quarterly revenue came in slightly ahead at $12.73 billion, edging past the consensus of $12.72 billion.
Looking ahead, Eli Lilly narrowed its full-year guidance. It now expects fiscal 2025 EPS in the range of $20.78 to $22.28, falling short of the $22.40 analysts had penciled in. Revenue is projected between $58 billion and $61 billion, bracketing the average estimate of $59.57 billion.
Lilly's stock had gained nearly 11% over the past three months and was up about 14% year-on-year before the sell-off. The results come amid a string of recent downward revisions to its EPS outlook, with five cuts and no upgrades in the past 90 days.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10